Glasses zoom letter

Frequently Asked Questions


  • What is the focus of Carl Zeiss Meditec AG's business activities?

    Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases - including implants and consumable materials.

    The company creates innovative visualisation solutions in the field of microsurgery. Carl Zeiss Meditec's medical technology portfolio is rounded off by promising future technologies such as intraoperative radiation therapy.


    In the 2010/2011 (30 September) financial year the over 2,300 employees generated revenue of approximately € 759 million. The head office of Carl Zeiss Meditec is in Jena, Germany. The company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France.


    Thirty-five percent of the Carl Zeiss Meditec shares are in free float. The remaining 65 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and opto-electronics industry. Carl Zeiss offers innovative solutions for the future-oriented markets "Medical and Research Solutions", "Industrial Solutions" and "Lifestyle Products". The head office of Carl Zeiss AG is in Oberkochen, Germany. In financial year 2010/2011 (balance sheet date: 30 September) the Group generated revenue of around € 4.2 billion. Carl Zeiss employs over 24,000 staff, over 10,000 thereof in Germany.

  • What are the cornerstones of the Carl Zeiss Meditec strategy?

    In spite of the difficult global economic climate, we are seeing a growth in demand for our diagnostic and therapeutic products, due to fundamental trends, such as a continuously aging global population. This applies to both ophthalmology and microsurgery and assures us that the good selling conditions for our products will continue.


    The program MEGA (Meditec Excellence and Growth Agenda) is aimed to focus the Company on the areas critical to success, and to process these in a target-oriented manner. The individual focus areas are “innovation”, “new markets”, “customer care”, “process excellence” and “employees”. We have made major progress in each of these areas, and the Company is now benefiting from this. What we have to do now is to continue the course we have taken and to secure a continued high-income future for the group.




    In the past business year we unveiled ReLex® smile, a new generation of high-precision femtosecond technology. Furthermore, our BLUEMIXS™ 180 injector is the first injector available on the market that already incorporates the extensive pallet of refractive MICS intraocular lenses (multifocal, toric and multifocal toric IOLs) and guarantees fast and reliable insertion of the lens into the eye.


    New markets


    With the VISALIS® 100 Phaco device we introduced a system which was specially geared to the needs of the fast-developing national economies (RDEs) and has quickly established itself on these markets. However, we are also aware that meeting customer needs demands a stronger presence on location. Carl Zeiss Meditec recently opened its “CARIn” centre of application and research in India. We are therefore increasing our presence in growth markets like India and are investing more selectively in research and development projects.


    Customer focus


    We are constantly working to improve our customer orientation and to be a reliable and sought-after partner for our customers. The constant expansion of our global service business thus remains a central concern and a key contributor to growth over the next few years. Within the past financial year, we therefore continued to invest in our Service business in order to continuously optimize customer care processes, from installation, through modernization, to expansions.


    Process excellence


    Our aim is to surpass our customers' expectations with excellent quality. This requires stable processes in all areas of the Company that are constantly further developed. One example is our new, optimized logistics concept in the area of surgical ophthalmology, which we set up during the past financial year. As a result of investment in a uniform logistics and IT structure for all surgical ophthalmology products, replacement orders by our customers can be assembled more quickly and forwarded to our central product warehouse. In Germany alone this has enabled us to double deliveries of intraocular lenses and consumables within a period of four years.




    Forward-looking human resources policy emphasizes sustainable and targeted development of the potential of all employees. The first signs of success are already visible within the framework of MEGA. Our aim is to expand and continue these in future. In this connection, for example the mentoring program that we have put in place, the intensified employee training and a systematic plan for management successors are of key importance.

  • Which are the main products of Carl Zeiss Meditec AG?

    Carl Zeiss Meditec has an extensive and innovative portfolio of products for the diagnosis and treatment of major eye ailments. These include:

    • the Cirrus™ HD-OCT a optical coherence tomography system which provides unique views of retina based on precise segmenting algorithms and high quality 3D images (for example, early diagnosis of glaucoma and retinal disorders).
    • the IOLMASTER® for accurate and efficient non-contact measurement of the eye prior to a cataract operation.

    • AT.Lisa, the world’s first genuine multifocal microincision lens (MICS) for presbyopia through a microincision of up to 1.5 mm.

    • the Humphrey® Field Analyzer for static and kinetic measurement of the visual field in support of glaucoma diagnosis.

    • the Femtosecondlaser VisuMax® which sets new standards with precise beam guidance and a balanced relationship of repetition rate and laser pulse energy for accurate and gentle treatment.

    ReLex® smile, a minimally invasive procedure for the correction of vision defects. This procedure enables physicians to operate accurately and in the least invasive way possible. In addition, the ReLEx smile is the first procedure by which the complete refractive correction can be performed solely with the VisuMax femtosecond laser. This innovation means that the patient does not need to be moved to another laser during the operation.

    • the surgical microscope OPMI Lumera® developed specially for ophthalmology. This is a microscope with Stereo Coaxial Illumination. This new procedure enables a combination of a good, bright, homogeneous red reflex with excellent contrast.

    INTRABEAM®, an innovative radiation therapy device by Carl Zeiss which is used for intraoperative radiotherapy of all solid tumors. The INTRABEAM device utilizes soft, short-range x-ray radiation and brings the radiation directly into the tumor or the tumor bed. The INTRABEAM irradiation unit permits a gentle and at the same time highly effective treatment.


  • In which indices are Carl Zeiss Meditec shares represented?

    Carl Zeiss Meditec shares are represented in TecDAX, CDAX, DAX International Mid 100, DAXsector All Pharma & Healthcare, DAXsubsector All Medical Technology, DAXsubsector Medical Technology, Prime All Share, Technology All Share, DAXglobal Sarasin Sustainability German Index, MIDCAP MKT P-IN and HDAX.


Annual General Meeting

  • How and where can a shareholder register for the AGM?

    About four weeks prior to the appointed date, shareholders will receive an invitation to the AGM, together with the agenda, through their custodian banks. Shareholders can use the corresponding reply form either to request an admission ticket or to issue a proxy authorisation to the bank. Further formal information can be found in the section “Annual General Meeting” in the current Articles of Association (PDF, 73 kB) of Carl Zeiss Meditec AG.


    In addition, Carl Zeiss Meditec acknowledges the recommendations of the German Corporate Government Codex for the support of shareholders in exercising their right to vote. Accordingly, shareholders may also authorise the company’s proxies to represent them. Further details will be included on the respective invitation to the AGM as soon as it has been issued.